Developing B cells must assemble and express genes encoding the immunoglobulin heavy (*Igh*) and light (*Igl*) chains of the B cell receptor (BCR; [@bib37]). This process occurs through V(D)J recombination, a reaction that assembles the second exon of lymphocyte antigen receptor genes from component variable (V), joining (J), and, at some loci, diversity (D) gene segments ([@bib15]). V(D)J recombination is initiated when the RAG endonuclease, composed of RAG-1 and RAG-2, introduces DNA double-strand breaks (DSBs) at a pair of recombining gene segments, generating two blunt signal DNA ends and two hairpin-sealed coding DNA ends ([@bib15]). RAG DSBs are generated in G1 phase lymphocytes, where they activate the ataxia-telangiectasia mutated (ATM) DNA damage response (DDR) kinase ([@bib12]; [@bib21]). In G1-phase cells, ATM inhibits S-phase entry by initiating canonical cell cycle checkpoint pathways through induction of p53 and directs DSB repair by nonhomologous end joining (NHEJ; [@bib42]; [@bib21]). In addition, in response to RAG DSBs, ATM activates a genetic program that may function to regulate processes required for normal lymphocyte development ([@bib5]; [@bib2]; [@bib21]; [@bib44]).

B cell development requires the sequential assembly of *Igh* chain genes in pro--B cells and *Igl* chain genes (*Igl* κ \[*Igk*\] or *Igl* λ) in pre--B cells ([@bib37]). The ordered assembly of immunoglobulin receptor genes is directed by signals from cell surface receptors. The IL-7r signals through AKT and JAK--STAT pathways to promote survival and to regulate *Igh* chain gene rearrangement in pro--B cells ([@bib4]; [@bib10]). Productive assembly of an *Igh* chain gene leads to its expression with the surrogate light chain (λ5 and Vpre--B) and the CD79A--CD79B heterodimer (Igα and Igβ, respectively) to generate the pre--BCR ([@bib24]; [@bib38]). Oligomerization of the pre--BCR, through ligand-dependent or -independent mechanisms, activates the SYK tyrosine kinase, leading to phosphorylation of the adaptor protein BLNK (also known as SLP-65; [@bib24]; [@bib38]).

Pre--BCR signals, along with those from the IL-7r, promote the developmental transition of pro--B cells to rapidly cycling, large pre--B cells ([@bib24]; [@bib38]; [@bib10]). Pre--BCR and IL-7r signals synergize to drive proliferation, whereas they independently regulate differentiation and survival, respectively. Activation of STAT5 by the IL-7r inhibits *Igk* germline transcription and activation of AKT by the IL-7r inhibits *Rag1* and *Rag2* gene expression, both of which prevent *Igk* gene assembly ([@bib1]; [@bib28], [@bib29]; [@bib11]; [@bib31]). Moreover, in cycling cells RAG-2 is degraded in S-phase ([@bib12]). Thus, proliferative signals must be attenuated for large pre--B cells to transit to the small pre--B cell stage where *Igk* chain gene assembly is initiated ([@bib39]; [@bib26]; [@bib31]; [@bib10]). IL-7r signals are attenuated by the pre--BCR, which inhibits AKT, a key molecule downstream of the IL-7r ([@bib23]; [@bib31]). Additionally, pre--BCR signals induce CXCR4, which can affect the localization of pre--B cells with respect to IL-7--producing stromal cells ([@bib49]; [@bib26]). Moreover, activation of RAS by the pre--BCR in large pre--B cells promotes exit from the cell cycle ([@bib28]). Loss of IL-7r signaling leads to increased SYK and BLNK expression, which reinforces pre--BCR signaling ([@bib31]).

Pre--BCR signals are required to initiate *Igk* chain gene assembly through activation of transcription factors and histone modifications that regulate *Igk* accessibility and RAG recruitment ([@bib10]). The pre--BCR induces expression of IRF4, which, together with PU.1, binds the 3′ *Igk* enhancer to promote *Igk* germline transcription and rearrangement ([@bib35]; [@bib26]; [@bib10]). Small pre--B cells often undergo multiple sequential *Igk* rearrangements over several days as they attempt to generate a functional *Igk* chain gene ([@bib8]). Once RAG DSBs are generated, the pre--BCR must be prevented from initiating additional *Igk* rearrangements. Moreover, activation of SYK by the pre--BCR could drive small pre--B cells with RAG DSBs into cycle ([@bib40]; [@bib51]; [@bib24]; [@bib38]). In pre--B cells, RAG DSBs activate canonical cell cycle checkpoint pathways, including p53 ([@bib17]; [@bib21]). However, in other cell types these checkpoint pathways can be overridden by proliferative signals, such as those from cytokine receptors ([@bib36]; [@bib43]). Thus, unopposed pre--BCR signaling could drive pre--B cells with RAG DSBs into cycle promoting aberrant RAG DSB repair and genome instability.

We reasoned that pre--BCR signaling must be regulated to order *Igk* chain gene assembly and prevent these signals from driving pre--B cells with RAG DSBs into cycle. Indeed, we show here that RAG DSBs activate a cell type--specific checkpoint pathway that inhibits pre--BCR signaling. This checkpoint pathway suppresses SYK and BLNK expression, inactivating pre--BCR signals to both prevent cell cycle progression and regulate *Igk* chain gene assembly. We propose that pre--B cells toggle between pre--BCR signaling and this RAG DSB-dependent checkpoint pathway, allowing for iterative *Igk* chain gene assembly while maintaining genome stability.

RESULTS {#s01}
=======

RAG DSB signals regulate the genetic program of small pre--B cells {#s02}
------------------------------------------------------------------

To elucidate the pre--B cell genetic program regulated by RAG DSB signals, we used mice deficient in RAG-1 or the Artemis endonuclease that express the *μIgh* and *Bcl2* transgenes (*Rag1^−/−^:μIgh:Bcl2* and *Art^−/−^:μIgh:Bcl2*, respectively; [@bib2]). The *μIgh* transgene enables formation of a pre--BCR, allowing for pre--B cell development in these mice, and the *Bcl2* transgene supports pre--B cell survival in vitro ([@bib2]). Culturing bone marrow from these mice in the presence of IL-7 leads to the selective expansion of large pre--B cells ([@bib39]; [@bib26]; [@bib2]). Upon withdrawal of IL-7, these cells transit to the small pre--B cell stage and induce RAG expression ([@bib2]; [@bib44]; [Fig. S1](http://www.jem.org/cgi/content/full/jem.20151048/DC1){#supp1}). *Rag1^−/−^:μIgh:Bcl2* small pre--B cells do not generate RAG DSBs. *Art^−/−^:μIgh:Bcl2* small pre--B cells generate RAG DSBs at *Igk*, but these DSBs are not repaired because Artemis is required to open hairpin-sealed coding DNA ends ([@bib21]; [Fig. 1 A](#fig1){ref-type="fig"}). These DSBs activate DDR, as indicated by phosphorylation of p53 ([Fig. 1 B](#fig1){ref-type="fig"}).

![**RAG DSBs regulate the genetic program in small pre--B cells.** (A) Southern blot of *SacI* and *EcoRI* digested genomic DNA from *Rag1^−/−^:μIgH:Bcl2, Art^−/−^:μIgH:Bcl2* and *Art^−/−^:Atm^−/−^:μIgH:Bcl2* small pre--B cells in IL-7 (0 d) and after withdrawal of IL-7 (IL-7 wd) for the indicated days. Bands reflecting the germline (GL) *Igk* locus and Jk coding ends (Jk1, Jk2, Jk4, and Jk5 CE) are indicated as are molecular weight markers in kilobases. (B) Western blot of phosphorylated p53 (p-p53) in pre--B cells in IL-7 (0 d) and after withdrawal of IL-7 (IL-7 wd) for the indicated days. GAPDH is shown as a protein loading control. Data in A and B are representative of at least three independent experiments. (C) Heat map of gene expression changes in *Rag1^−/−^:μIgH:Bcl2* and *Art^−/−^:μIgH:Bcl2* pre--B cells in the presence of IL-7 (+ IL-7) and 2 d after IL-7 withdrawal (− IL-7). Columns represent three independent cell cultures of each genotype. Representative genes are delineated to the right. (D and E) RT-PCR validation of representative RAG DSB-independent (D) or RAG DSB-dependent (E) gene expression changes from C. mRNA expression was assessed in *Rag1^−/−^:μIgH:Bcl2* (black) and *Art^−/−^:μIgH:Bcl2* (red) pre--B cells in the presence of IL-7 (+ IL-7) and 2 d after IL-7 withdrawal (− IL-7). Data are mean and standard error for three replicates. (F) Venn diagram comparing gene expression changes that occur during the transition of large to small pre--B cells in the bone marrow of WT mice (ImmGen; blue) and gene expression changes we observe in small pre--B cells after withdrawal of IL-7 (red). The ImmGen data represents all genes that were significantly changed (p-value \< 0.05) between large and small pre--B cells. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.005; \*\*\*\*, P ≤ 0.0001 by Student's *t* test.](JEM_20151048_Fig1){#fig1}

Gene profiling revealed that ∼3,000 genes change in expression (\>1.5-fold) in *Art^−/−^:μIgh:Bcl2* or *Rag1^−/−^:μIgh:Bcl2* pre--B cells as they transition from large (in IL-7) to small (IL-7 withdrawal) pre--B cells ([Fig. 1, C-E](#fig1){ref-type="fig"}; and [Table S1](http://www.jem.org/cgi/content/full/jem.20151048/DC1){#supp2}). Many of these gene expression changes are observed during B cell development in vivo ([@bib22]; [Fig. 1 F](#fig1){ref-type="fig"}). Comparison of *Art^−/−^:μIgh:Bcl2* and *Rag1^−/−^:μIgh:Bcl2* small pre--B cells reveals that RAG DSB signals regulate a significant fraction (∼40%) of the gene expression changes that occur during the transition of large to small pre--B cells (RAG DSB dependent; [Fig. 1, C--E](#fig1){ref-type="fig"}; and Table S1).

ATM and NIK activate NF-κB2 in small pre--B cells {#s03}
-------------------------------------------------

In small pre--B cells, RAG DSBs induce expression of the *Relb* and *Nfkb2* (p100) genes, which encode the principal components of the noncanonical NF-κB (NF-κB2) pathway ([@bib20]; [@bib46]; [Fig. 2 A](#fig2){ref-type="fig"} and Table S1). This depends on the activation of ATM as revealed by analyses of *Art^−/−^:Atm^−/−^:μIgh:Bcl2* small pre--B cells in vitro and *Atm^−/−^* pre--B cells in vivo ([Fig. 2, A and B](#fig2){ref-type="fig"}). The p100 and RELB proteins are induced by RAG DSBs (compare *Art^−/−^:μIgh:Bcl2* and *Rag1^−/−^:μIgh:Bcl2*) in small pre--B cells that express ATM and have intact DDR signals (compare *Art^−/−^:μIgh:Bcl2* and *Art^−/−^:Atm^−/−^:μIgh:Bcl2*; [Fig. 2 C](#fig2){ref-type="fig"}). Formation of the transcriptionally active p52-RELB heterodimer, which translocates to the nucleus, requires cleavage of p100 to form p52 ([@bib20]; [@bib46]). In this regard, the robust generation of p52 and the nuclear translocation of p52 and RELB are observed only in small pre--B cells with RAG DSBs ([Fig. 2, C and D](#fig2){ref-type="fig"}). In mature B cells, cleavage of p100 to form p52 depends on the NF-κB--inducing kinase (NIK; [@bib20]; [@bib46]). Similarly, in small pre--B cells NIK is required for the generation of p52, as *Art^−/−^:Nik^−/−^:μIgh:Bcl2* small pre--B cells show induction of p100 in response to RAG DSBs, but inefficient conversion of p100 to p52 ([Fig. 2 E](#fig2){ref-type="fig"}). Thus, NF-κB2 is activated in small pre--B cells through the RAG DSB-dependent induction of p100 and RELB coupled with the NIK-dependent conversion of p100 to p52.

![**Signals from RAG DSBs activate NF-κB2.** (A) *Nfkb2* and *Relb* mRNA expression in *Rag1^−/−^:μIgH:Bcl2* (black), *Art^−/−^:μIgH:Bcl2* (red), and *Art^−/−^:Atm^−/−^;μIgH:Bcl2* (blue) small pre--B cells 2 d after IL-7 withdrawal. Data are mean and standard error for three replicates. (B) *Nfkb2* and *Relb* mRNA expression in sorted small pre--B cells from *Rag1^−/−^:μIgH:Bcl2*, WT, and Atm^−/−^ mice. Data are mean and standard error from three independent mice of each genotype. (C) Western blot of NF-κB2 (p100 and p52) and RELB in pre--B cells in IL-7 (0 d) and after withdrawal of IL-7 (IL-7 wd) for the indicated days. GAPDH is shown as a protein loading control. (D) Western blot of NF-κB2 (p100 and p52) and RELB incytoplasmic andnuclear fractions from pre--B cells in IL-7 (0 d) and after withdrawal of IL-7 for the indicated days. LaminB and GAPDH are shown as protein loading controls for nuclear and cytoplasmic fractions, respectively. (E) Western blot of NF-κB2 (p100 and p52) in pre--B cells in IL-7 (0 d) and after withdrawal of IL-7 (IL-7 wd) for the indicated days. GAPDH is shown as a protein loading control. Data in all panels are representative of at least three independent experiments. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.005 by Student's *t* test.](JEM_20151048_Fig2){#fig2}

NF-κB2 induces SPIC expression {#s04}
------------------------------

Analysis of *Art^−/−^:μIgh:Bcl2* and *Art^−/−^:Nfkb2^−/−^:μIgh:Bcl2* small pre--B cells revealed that ∼15% of the genes regulated by RAG DSBs depend on NF-κB2 ([Fig. 3 A](#fig3){ref-type="fig"} and [Table S2](http://www.jem.org/cgi/content/full/jem.20151048/DC1){#supp3}). One of these genes encodes SPIC, an ETS family transcription factor with significant homology to PU.1 and SPIB ([@bib3]; [@bib19]). Induction of *Spic* in response to RAG DSBs depends on ATM and NF-κB2, as indicated by analysis of *Art^−/−^:μIgh:Bcl2*, *Art^−/−^:Atm^−/−^:μIgh:Bcl2*, and *Art^−/−^:Nfkb2^−/−^:μIgh:Bcl2* small pre--B cells ([Fig. 3 B](#fig3){ref-type="fig"}). To assess SPIC expression in vivo, we used mice with a *Spic* reporter allele, *Spic^igfp^*, which contains an IRES-EGFP targeted to a 3′ noncoding exon of the *Spic* gene ([@bib18]). Approximately 40% of bone marrow small pre--B cells from *Art^−/−^:Spic^igfp/igfp^:μIgh:Bcl2* mice express EGFP ([Fig. 3 C](#fig3){ref-type="fig"}). CD40 surface expression is induced by RAG DSB signals, and thus functions as a marker of small pre--B cells with RAG DSBs ([@bib5]). All of the EGFP-positive small pre--B cells in *Art^−/−^:Spic^igfp/igfp^:μIgh:Bcl2* mice also express CD40 ([Fig. 3 C](#fig3){ref-type="fig"}). In contrast, none of the small pre--B cells from *Rag1^−/−^:Spic^igfp/igfp^:μIgh:Bcl2* mice express EGFP or CD40 ([Fig. 3 C](#fig3){ref-type="fig"}). Together, these data are consistent with the interpretation that SPIC expression in small pre--B cells is induced by RAG DSBs through the sequential activation of ATM and NF-κB2.

![**Signals from RAG DSBs induce SPIC expression.** (A) Heat map of RAG DSB-dependent gene expression changes that require NF-κB2. *Art^−/−^:μIgH:Bcl2* pre--B cells were compared with *Rag1^−/−^:μIgH:Bcl2* pre--B cells to identify RAG DSB-dependent gene expression changes followed by comparison of *Art^−/−^:μIgH:Bcl2* and *Art^−/−^:Nfkb2^−/−^:μIgH:Bcl2* pre--B cells to identify NF-κB2--dependent changes. Columns represent three independent cell cultures of each genotype. Representative genes are delineated to the right. (B) *Spic* mRNA expression in *Rag1^−/−^:μIgH:Bcl2* (black), *Art^−/−^:μIgH:Bcl2* (red), *Art^−/−^:Atm^−/−^:μIgH:Bcl2* (blue), and *Art^−/−^:Nfkb2^−/−^:μIgH:Bcl2* (green) small pre--B cells 2 d after IL-7 withdrawal. Data are mean and standard error for three replicates. (C) Flow cytometric analysis of CD40 (y-axis) and EGFP (x-axis) expression in bone marrow small pre--B cells (B220^lo^CD43^−^IgM^−^) from *Rag1^−/−^:Spic^igfp/igfp^:μIgH:Bcl2* and *Art^−/−^:Spic^igfp/igfp^:μIgH:Bcl2* mice. Inset shows percent of cells in each quadrant. Data are representative of three independent experiments. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.005 by Student's *t* test.](JEM_20151048_Fig3){#fig3}

RAG DSBs negatively regulate pre--BCR signaling {#s05}
-----------------------------------------------

Ectopic SPIC expression in mature B cells inhibits BCR signaling, and in lymphocyte progenitors it blocks B cell development at the pre--B cell stage ([@bib57]). As RAG DSBs induce SPIC, we reasoned that they might negatively regulate pre--BCR signaling. Indeed, we find that expression of both SYK and BLNK is reduced in small pre--B cells with RAG DSBs (*Art^−/−^:μIgh:Bcl2*) but not in those without RAG DSBs (*Rag1^−/−^:μIgh:Bcl2*) or in ATM-deficient (*Art^−/−^:Atm^−/−^:μIgh:Bcl2*) pre--B cells with RAG DSBs ([Fig. 4, A--D](#fig4){ref-type="fig"}). Consistent with the reduction in these proteins, small pre--B cells with RAG DSBs have decreased pre--BCR signaling as evidence by reduced levels of phosphorylated BLNK ([Fig. 4 A](#fig4){ref-type="fig"}). Expression of BTK, another pre--BCR signaling protein, is not affected by RAG DSBs but is minimally decreased by loss of IL-7r signals ([Fig. 4, E and F](#fig4){ref-type="fig"}). Retroviral expression of SPIC in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells leads to inhibition of both *Blnk* and *Syk* expression ([Fig. 5 A](#fig5){ref-type="fig"}). Moreover, SPIC-expressing (EGFP-positive) small pre--B cells in *Spic^igfp/igfp^* mice have lower levels of *Syk* and *Blnk* transcripts as compared with cells that do not express SPIC (EGFP negative; [Fig. 5 B](#fig5){ref-type="fig"}). We conclude that RAG DSBs antagonize the expression of two key pre--BCR signaling proteins, SYK and BLNK, through the sequential induction of ATM, NF-κB2, and SPIC.

![**RAG DSBs suppress pre--BCR signaling.** (A) Western blot of phosphorylated BLNK (p-BLNK) and total BLNK in pre--B cells in IL-7 (0 d) and following IL-7 withdrawal (IL-7 wd) for the indicated days. GAPDH is shown as a protein loading control. (B and C) Western blot of SYK in pre--B cells cultured in IL-7 (+) and 3 d after IL-7 withdrawal (--). GAPDH is shown as a protein loading control. (D and E) *Blnk*, *Syk* and *Btk* mRNA expression in *Rag1^−/−^:μIgH:Bcl2* (black), *Art^−/−^:μIgH:Bcl2* (red), and *Art^−/−^:Atm^−/−^;μIgH:Bcl2* (blue) small pre--B cells 3 d after IL-7 withdrawal. Data are mean and standard error for three replicates. (F) Western blot of BTK in pre--B cells cultured in IL-7 (+) and 3 d after IL-7 withdrawal (--). GAPDH is shown as a protein loading control. Data in A, B, C, and F are representative of at least three independent experiments. \*, P ≤ 0.05; \*\*\*, P ≤ 0.005; \*\*\*\*, P ≤ 0.0001 by Student's *t* test.](JEM_20151048_Fig4){#fig4}

![**SPIC inhibits expression of *Syk* and *Blnk*.** (A) *Rag1^−/−^:μIgH:Bcl2* small pre--B cells were transduced with an empty retrovirus or a retrovirus expressing SPIC. *Blnk* and *Syk* mRNA expression was assessed 2 d after IL-7 withdrawal. Data are mean and standard error for three replicates. (B) *Blnk* and *Syk* mRNA expression in EGFP-negative (--) and EGFP-expressing (+) small pre--B cells sorted from *Spic^igfp/igfp^* mice. Data are the mean and standard error from three independent mice. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.005 by Student's *t* test.](JEM_20151048_Fig5){#fig5}

SPIC antagonizes PU.1 binding at *Syk* and *Blnk* {#s06}
-------------------------------------------------

The expression of *Blnk* depends on PU.1 binding to its promoter ([@bib41]; [@bib52]). SPIC functions as a transcriptional repressor that recognizes the same DNA sequence as PU.1 but, unlike PU.1, SPIC is unable to bind IRF4, which is required to initiate transcription ([@bib3]; [@bib19]; [@bib7]). To determine whether SPIC induction by RAG DSBs affects PU.1 activity, we compared PU.1 binding at *Blnk* in *Art^−/−^:μIgh:Bcl2* and *Rag1^−/−^:μIgh:Bcl2* small pre--B cells. Although PU.1 levels are similar in these cells, binding of PU.1 to the *Blnk* promoter is markedly reduced in *Art^−/−^:μIgh:Bcl2* small pre--B cells, which have RAG DSBs and up-regulate SPIC, as compared with *Rag1^−/−^:μIgh:Bcl2* small pre--B cells that do not express SPIC ([Fig. 6, A and B](#fig6){ref-type="fig"}). When SPIC is retrovirally expressed in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells, we observe SPIC binding to both the *Blnk* promoter and a putative regulatory element upstream of the *Syk* gene ([@bib56]; [Fig. 6, C and D](#fig6){ref-type="fig"}). Moreover, we also observe decreased PU.1 binding at these regulatory elements in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells expressing SPIC ([Fig. 6 E](#fig6){ref-type="fig"}). Mutation of the conserved Ets domain (R175G) in SPIC (SPIC^R175G^) ablates SPIC binding to *Blnk* and *Syk*, similar to previous findings for PU.1 ([@bib34]; [@bib47]; and unpublished data). Compared with SPIC, equivalent expression of SPIC^R175G^ in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells does not result in decreased PU.1 binding at *Blnk* and *Syk* ([Fig. 6, C and E](#fig6){ref-type="fig"}). Together, these data suggest that, after induction by RAG DSBs, SPIC directly antagonizes PU.1 at cis-acting regulatory elements in both the *Blnk* and *Syk* loci.

![**SPIC displaces PU.1 from *Syk* and *Blnk*.** (A) Western blot of PU.1 in pre--B cells cultured in IL-7 (+) and 3 d after IL-7 withdrawal (--). GAPDH is shown as a protein loading control. (B) ChIP-qPCR of PU.1 binding at the *Blnk* promoter in *Rag1^−/−^:μIgH:Bcl2* and *Art^−/−^:μIgH:Bcl2* small pre--B cells 3 d after IL-7 withdrawal. (C--E) *Rag1^−/−^:μIgH:Bcl2* small pre--B cells were transduced with an empty retrovirus, a retrovirus expressing SPIC, or a retrovirus expressing a DNA binding--deficient SPIC (SPIC^R175G^). (C) Western blot of FLAG was performed 2 d after IL-7 withdrawal. GAPDH is shown as a protein loading control. ChIP-qPCR of SPIC binding (D) and PU.1 binding (E) at the *Blnk* promoter and at a putative regulatory element located 10-kb upstream of the transcription start site for *Syk* was performed 2 d after IL-7 withdrawal. Data in all panels are representative of two independent experiments.](JEM_20151048_Fig6){#fig6}

SPIC inhibits germline transcription and RAG cleavage at *Igk* {#s07}
--------------------------------------------------------------

SYK and BLNK signals from the pre--BCR induce IRF4 to promote germline transcription and rearrangement of the *Igk* locus. Inhibition of pre--BCR signaling by RAG DSBs could feed back to suppress this process. Indeed, small pre--B cells with RAG DSBs (*Art^−/−^:μIgh:Bcl2*) exhibit decreased IRF4 expression and *Igk* germline transcripts as compared with *Rag1^−/−^:μIgh:Bcl2* small pre--B cells ([Fig. 7, A and B](#fig7){ref-type="fig"}). Moreover, retroviral expression of SPIC in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells leads to a reduction in both *Irf4* and germline *Igk* transcripts ([Fig. 7 C](#fig7){ref-type="fig"}). Germline *Igk* transcription requires PU.1 binding at 3′ *Igk* enhancer, which is significantly reduced in *Art^−/−^:μIgh:Bcl2* small pre--B cells with RAG DSBs as compared with *Rag1^−/−^:μIgh:Bcl2* small pre--B cells ([Fig. 7 D](#fig7){ref-type="fig"}). Moreover, when SPIC is retrovirally expressed in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells, we observe SPIC binding at the 3′ *Igk* enhancer and a concomitant decrease in PU.1 binding ([Fig. 7, E and F](#fig7){ref-type="fig"}). Thus, SPIC negatively regulates germline *Igk* transcription both by inhibiting pre--BCR signals that lead to IRF4 expression and by interfering with PU.1 binding at the 3′ *Igk* enhancer.

![**SPIC inhibits *Igl* transcription and rearrangement.** (A) *Irf4* and germline *Igk* mRNA expression in *Rag1^−/−^:μIgH:Bcl2* and *Art^−/−^:μIgH:Bcl2* small pre--B cells assessed 3 d after IL-7 withdrawal. Data are mean and standard error for three replicate experiments. (B) Western blot of IRF4 in pre--B cells in IL-7 (0 d) and after IL-7 withdrawal (IL-7 wd) for the indicated days. GAPDH is shown as a protein loading control. Data are representative of three independent experiments. (C) *Rag1^−/−^:μIgH:Bcl2* small pre--B cells were transduced with an empty retrovirus or a retrovirus expressing SPIC. *Irf4* and germline *Igk* mRNA expression were assessed 2 d after IL-7 withdrawal. Data are mean and standard error for three replicate experiments. (D) ChIP-qPCR of PU.1 binding at the 3′ *Igk* enhancer in *Rag1^−/−^:μIgH:Bcl2* and *Art^−/−^:μIgH:Bcl2* small pre--B cells 3 d after IL-7 withdrawal. (E and F) *Rag1^−/−^:μIgH:Bcl2* small pre--B cells were transduced with an empty retrovirus or a retrovirus expressing SPIC. ChIP-qPCR of SPIC binding (E) and PU.1 binding (F) at the 3′ *Igk* enhancer was performed 2 d after IL-7 withdrawal. (G) Southern blot of *SacI* and *EcoRI* digested genomic DNA from *Art^−/−^:Atm^−/−^:μIgH:Bcl2* small pre--B cells transduced with an empty retrovirus or a retrovirus expressing SPIC 3 d after IL-7 withdrawal. Bands reflecting the germline (GL) *Igk* locus and Jk coding ends (Jk1, Jk2, Jk4, and Jk5 CE) are indicated as are molecular weight markers in kilobases. Data in D--G are representative of two independent experiments. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.005 by Student's *t* test.](JEM_20151048_Fig7){#fig7}

The activation of ATM by *Igk* rearrangements feeds back to inhibit the generation of additional RAG DSBs as indicated by increased RAG cleavage at *Igk* in *Art^−/−^:Atm^−/−^:μIgh:Bcl2* as compared with *Art^−/−^:μIgh:Bcl2* small pre--B cells ([@bib25]; [@bib44]; [Fig. 1 A](#fig1){ref-type="fig"}). Retroviral expression of SPIC in *Art^−/−^:Atm^−/−^:μIgh:Bcl2* small pre--B cells results in decreased RAG cleavage at *Igk* ([Fig. 7 G](#fig7){ref-type="fig"}). This is indicated by the increase in *Igk* loci in the germline configuration and a concomitant decrease in *Igk* coding ends in *Art^−/−^:Atm^−/−^:μIgh:Bcl2* small pre--B cells expressing SPIC as compared with *Art^−/−^:Atm^−/−^:μIgh:Bcl2* small pre--B cells expressing the empty retroviral vector ([Fig. 7 G](#fig7){ref-type="fig"}). We conclude that the ATM-dependent induction of SPIC by RAG DSBs in small pre--B cells feeds back to inhibit germline transcription and the generation of additional RAG DSBs at the *Igk* locus.

RAG DSBs inhibit pre--BCR--driven proliferation {#s08}
-----------------------------------------------

SYK activation downstream of the pre--BCR can drive small pre--B cells into cycle in the absence of IL-7r signals ([@bib40]; [@bib51]). Indeed, we find that *Rag1^−/−^:μIgh:Bcl2* small pre--B cells proliferate after IL-7 withdrawal, and this proliferation is blocked by the SYK kinase inhibitor BAY 61--3606 (unpublished data). Persistent pre--BCR signaling, and resulting SYK activation, could drive small pre--B cells with *Igk* RAG DSBs into cycle. Thus, inactivation of pre--BCR signaling may be required in addition to canonical cell cycle checkpoint pathways (p53) to enforce G1 arrest in small pre--B cells with RAG DSBs. In small pre--B cells, SYK activity is suppressed through sequential activation of NF-κB2 and SPIC by RAG DSBs ([Fig. 4, B--D](#fig4){ref-type="fig"}; and [Fig. 5 A](#fig5){ref-type="fig"}). Consistent with this, expression of NF-κB2 or SPIC in *Rag1^−/−^:μIgh:Bcl2* small pre--B cells is sufficient to reduce cell cycle entry ([Fig. 8, A and B](#fig8){ref-type="fig"}).

![**RAG DSBs inhibit pre--BCR-driven proliferation.** (A and B) *Rag1^−/−^:μIgH:Bcl2* small pre--B cells were transduced with an empty retrovirus or a retrovirus expressing NF-κB2 (A) or SPIC (B). Flow cytometric analysis of BrdU incorporation (y axis) and DNA content (7AAD; x axis) was performed after IL-7 withdrawal. Percentage of cells that entered S-phase during BrdU labeling (box) is indicated. Data are representative of at least three independent experiments. (C) Cell cycle analysis was performed as in A on *Art^−/−^:μIgH:Bcl2* small pre--B cells with RAG DSBs (CD40 pos) and those without RAG DSBs (CD40 neg) after IL-7 withdrawal. Percentage of cells that entered S-phase during BrdU labeling (box) is indicated. Data are representative of at least three independent experiments. (D) Cell cycle analysis of CD40 neg and CD40 pos *Art^−/−^:μIgH:Bcl2* and *Art^−/−^:p53^−/−^:μIgH* small pre--B cells as in C. Graph represents the percentage of cells that entered S-phase. Data are mean and standard error for two independent experiments. (E and F) *Art^−/−^:p53^−/−^:μIgH* (E) and *Art^−/−^:μIgH:Bcl2* (F) small pre--B cells were transduced with an empty retrovirus or a retrovirus expressing SYK. Cell cycle analysis of CD40 neg and CD40 pos pre--B cells was performed as in C. Graphs represent the percentage of cells that entered S-phase. Data in both panels are representative of three independent experiments. \*\*, P ≤ 0.01; \*\*\*\*, P ≤ 0.0001 by Student's *t* test.](JEM_20151048_Fig8){#fig8}

*Art^−/−^:μIgh:Bcl2* pre--B cells with RAG DSBs (CD40 pos), which both suppress SYK expression and activate p53, are arrested in the G1-phase of the cell cycle as compared with cells without RAG DSBs (CD40 neg; [Fig. 8 C](#fig8){ref-type="fig"}). Surprisingly, loss of p53 (*Art^−/−^:p53^−/−^:μIgh*) leads to only a modest increase in S-phase progression in cells with RAG DSBs (CD40 pos), suggesting that inhibition of pre--BCR signaling may also enforce G1 arrest in these cells ([Fig. 8 D](#fig8){ref-type="fig"}). Indeed, retroviral reconstitution of SYK significantly increases S-phase entry in *Art^−/−^:p53^−/−^:μIgh* small pre--B cells with RAG DSBs (CD40 pos; [Fig. 8 E](#fig8){ref-type="fig"}). Expression of SYK also increases S-phase entry in p53-sufficient *Art^−/−^:μIgh:Bcl2* small pre--B cells with RAG DSBs (CD40 pos), but to a lesser extent than that observed in p53-deficient cells ([Fig. 8, E and F](#fig8){ref-type="fig"}). Thus, in pre--B cells, RAG DSBs must activate both the canonical checkpoint (p53) and a cell type--specific checkpoint pathway that inhibits pre--BCR signals to affect a complete G1 arrest.

DISCUSSION {#s09}
==========

Here, we show that RAG DSBs activate a cell type--specific checkpoint pathway that functions to both enforce G1 cell cycle arrest and regulate *Igk* chain gene rearrangement in small pre--B cell. This occurs through the sequential activation of ATM and NF-κB2, which leads to induction of SPIC, a hematopoietic-specific transcriptional repressor. SPIC inhibits pre--BCR signaling by repressing the expression of SYK and BLNK. Additionally, SPIC directly antagonizes *Igk* locus germline transcription and rearrangement. Thus, signals from RAG DSBs generated during *Igk* gene assembly are integrated into the signaling circuitry of developing pre--B cells.

In mature B cells, p100 and RELB are constitutively expressed and NF-κB2 activation occurs upon engagement of CD40 or BAFF receptors with their respective ligands, leading to stabilization of NIK and conversion of p100 to p52. In resting cells, NIK exists in a complex with the cIAP ubiquitin ligases, which mediate NIK degradation ([@bib50]; [@bib55]; [@bib20]; [@bib46]). Signals from the CD40 or BAFF receptors trigger dissociation of this complex and increased NIK levels ([@bib50]; [@bib55]; [@bib20]; [@bib46]). Similar to mature B cells, pre--B cells require NIK to promote the conversion of p100 to p52 in response to RAG DSBs. However, in contrast to mature B cells, expression of p100 and RELB must be induced in pre--B cells, and this depends on the activation of ATM by RAG DSBs generated during *Igl* chain gene assembly. Thus, pre--B cells require the convergence of two signals (ATM and NIK) to activate NF-κB2.

In response to RAG DSBs, NF-κB2 induces the expression of SPIC, an ETS family transcription factor with homology to PU.1 and SPIB ([@bib3]; [@bib19]). PU.1 and SPIB are constitutively expressed in developing B cells, where they perform critical developmental functions ([@bib41]). In mature B cells, SPIC regulates BCR signaling and canonical NF-κB1 activation ([@bib57]; [@bib27]). How SPIC is regulated and functions in early B cells has not been determined. Here, we show that in developing B cells, SPIC is induced by RAG DSBs. Consequently, SPIC is only expressed in small pre--B cells that are actively undergoing *Igl* chain gene rearrangement. SPIC represses transcription by interfering with PU.1 binding to critical cis-acting regulatory elements at the *Igk* locus and at the *Blnk* and *Syk* genes. In doing so, SPIC suppresses pre--BCR signaling, thereby enforcing a cell type--specific checkpoint in pre--B cells in response to RAG DSBs.

In large pre--B cells, signals from the pre--BCR attenuate IL-7r signals, which is required for transition to the small pre--B cell stage and for initiation of *Igk* chain gene assembly ([@bib39]; [@bib26]; [@bib28]; [@bib31]; [@bib10]). The pre--BCR signals through BLNK to antagonize AKT signaling downstream of the IL-7r ([@bib23]; [@bib31]). Attenuation of IL-7r signaling leads to increased expression of SYK and BLNK, which further augments pre--BCR signaling ([@bib31]). We show that once *Igk* chain gene assembly has been initiated, RAG DSB signals feedback to inhibit the pre--BCR by suppressing the expression of SYK and BLNK, which could lead to reactivation of IL-7r signals. However, pre--BCR signals may also function to reposition small pre--B cells to bone marrow niches devoid of IL-7--producing stromal cells ([@bib49]; [@bib26]). Moreover, in small pre--B cells, RAG DSBs induce CD69, SWAP-70, and [l]{.smallcaps}-selectin, which function in lymphocyte trafficking and localization ([@bib5]). This could enforce localization of pre--B cells in IL-7 poor areas of the bone marrow once *Igk* chain assembly has initiated. RAG DSBs also induce the PIM2 kinase, which antagonizes IL-7r signals ([@bib2]). Thus, although pre--BCR signaling is required for the initial suppression of IL-7r signaling in small pre--B cells, continued pre--BCR signaling may not be required to maintain this suppression.

Initiation of pre--BCR signaling occurs upon the activation of SYK, which phosphorylates BLNK ([@bib24]; [@bib38]; [@bib10]). We find that RAG DSBs inactivate pre--BCR signaling by inhibiting both SYK and BLNK. Why would it be important for RAG DSBs to inhibit both proteins? In the absence of SYK, ZAP-70 can phosphorylate BLNK, activating downstream signaling cascades ([@bib9]; [@bib13]). Thus, the isolated inhibition of SYK would not attenuate pre--BCR signaling. BLNK antagonizes SYK activation by the pre--BCR ([@bib14]; [@bib48]). Consequently, the isolated loss of BLNK increases SYK activation ([@bib14]; [@bib48]). Indeed, both loss of BLNK and overactivation of SYK are associated with B cell transformation and leukemia ([@bib14]; [@bib48]; [@bib33]; [@bib16]). Thus, complete suppression of pre--BCR signaling by RAG DSBs would rely on the inactivation of both SYK and BLNK. Here, we have defined the signaling pathway that inhibits pre--BCR signaling under physiological conditions in normal pre--B cells. Conceivably, this pathway could be therapeutically targeted in pre--B cell leukemias that depend on pre--BCR signaling.

DNA DSBs activate p53-dependent canonical checkpoint pathways to prevent cell cycle progression until the DSBs have been repaired ([@bib42]). However, in some cell types proliferative signals can bypass p53-mediated checkpoints, driving cells with DSBs through cell cycle and promoting genome instability ([@bib36]; [@bib43]). RAG DSBs activate p53 in G1-phase small pre--B cells ([@bib17]). However, we find that even in the absence of p53, small pre--B cells with RAG DSBs are still arrested in G1. Furthermore, restoration of pre--BCR signaling through SYK expression overrides the p53-mediated checkpoint leading to the S-phase progression of small pre--B cells with RAG DSBs. Thus, enforcement of the G1--S checkpoint in small pre--B cells depends on activation of both the canonical checkpoint (p53) and a cell type--specific checkpoint pathway that inhibits pre--BCR proliferative signals. In the absence of ATM, these checkpoint pathways are defective. Consequently, ATM-deficient pre--B cells with RAG DSBs enter cell cycle and persist in the periphery for several weeks ([@bib6]).

Small pre--B cells undergo multiple rounds of *Igl* chain gene rearrangement over a span of several days as they attempt to generate a productive Igl chain that can pair with the Igh chain to form a nonautoreactive BCR ([@bib37]; [@bib8]). Pre--BCR signals initiate *Igl* chain rearrangement through induction of IRF4 and subsequent activation of germline *Igk* transcription ([@bib26]; [@bib10]). Once RAG DSBs are generated in the *Igk* locus, additional RAG cleavage events must be inhibited. In this regard, we show that RAG DSBs suppress pre--BCR signaling, leading to a reduction in *Igk* germline transcription and inhibition of additional DSBs at the *Igk* locus. This occurs through the ATM- and NF-κB2--dependent induction of SPIC, which inhibits SYK and BLNK and interferes with PU.1 binding to the *Igk* enhancer. This feedback circuit prevents pre--B cells with RAG DSBs from entering cycle and prevents additional RAG DSBs at the *Igl* locus until the initial rearrangement has been completed and ATM signaling is terminated. If this rearrangement encodes an *Igk* chain that forms a functional BCR, the cell transits to the immature B cell stage. However, if the *Igk* chain gene is not functional, loss of ATM signaling would lead to the reexpression of SYK and BLNK, leading to reactivation of pre--BCR signaling and induction of another *Igk* chain gene rearrangement. We propose that small pre--B cells toggle between pre--BCR signals and a RAG DSB-dependent cell-type specific checkpoint to order iterative *Igl* chain gene rearrangements and maintain genomic stability by preventing pre--B cells with RAG DSBs from entering cell cycle.

MATERIALS AND METHODS {#s10}
=====================

 {#s11}

### Mice {#s12}

All mice were bred and maintained under specific pathogen--free conditions at the Washington University School of Medicine and were handled in accordance to the guidelines set forth by the Division of Comparative Medicine of Washington University. Wild-type B6 mice (The Jackson Laboratory) were used as controls. *p53^−/−^* mice were purchased from The Jackson Laboratory. *Spic^igfp/igfp^*, *Nik^−/−^*, and *Nfkb2^−/−^* mice were generated as previously described ([@bib53]; [@bib54]; [@bib18]). *Spic^igfp/igfp^* mice were on a B6 background. All other mice are on a mixed genetic background. In vivo studies were conducted on 4--5-wk-old mice.

### Cell culture {#s13}

Primary pre--B cell cultures were generated from bone marrow harvested from 4--6-wk-old mice and cultured for 7--10 d at 2 × 10^6^ cells/ml in media containing 5 ng/ml of IL-7 (Life Technologies). For IL-7 withdrawal experiments, cells were resuspended in media without IL-7 and maintained at 2 × 10^6^ cells/ml.

### Retroviral transduction and cDNA expression {#s14}

pMSCV-mCherry-SYK was purchased from Addgene (plasmid 50045; [@bib45]). cDNA encoding SPIC with a 5′Flag tag was cloned into the pOZ retrovirus containing an IRES sequence, followed by truncated human CD25 (hCD25) cDNA as a marker of transduced cells. A DNA binding--deficient SPIC was generated by mutating arginine 175 to glycine (R175G) using QuikChange II XL (Agilent) according to the manufacturer's protocol ([@bib34]; [@bib47]). Retrovirus was produced in platE cells by transfection of the retroviral plasmid with Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Viral supernatant was collected and pooled from 24--72 h after transfection. Viral supernatant was used immediately to transduce cells or was concentrated before transduction. To concentrated viral particles, PEG-8000 (Sigma-Aldrich; final concentration 8%) was added to viral supernatant, incubation at 4°C overnight, and centrifugation at 2,500 RPM for 20 min. Precipitated virus was resuspended at 300× concentration in sterile PBS. Pre--B cells were transduced with unconcentrated virus (40 × 10^6^ cells in 3 ml viral supernatant) or with concentrated virus (40 × 10^6^ in 1 ml with 10× viral particles) in IL-7--containing media with polybrene (5 µg/ml; Sigma-Aldrich) by centrifugation for 2 h at 1,200 RPM at room temperature. 4 h later, fresh IL-7 media (2 mls) was added, and the cells were incubated overnight. Virus-containing media was removed and cells were cultured in fresh IL-7 media (2 × 10^6^/ml). Cells expressing the retrovirus construct were identified by flow cytometric assessment of hCD25 or mCherry expression using a FACSCalibur (BD). Transduced cells were sorted using biotin-conjugated anti-hCD25 (BD) and anti-biotin magnetic beads (Miltenyi Biotec) on MS columns (Miltenyi Biotec) according to the manufacturer's protocol.

### Flow cytometric analyses and cell sorting {#s15}

Flow cytometric analyses were performed on a FACSCalibur or BD LSRFortessa (BD). Sorting was conducted on a BD Aria (user-operated) or on a Sony Sy3200 through the Siteman Cancer Center Flow Cytometry Core Facility. FITC-conjugated anti-CD45R/B220 (clone RA3-6B2), phycoerythrin (PE)-conjugated anti-CD43 (clone S7), FITC-conjugated anti-CD43 (clone S7), PE-Cy7--conjugated anti-CD45/B220 (clone RA3-6B2), allophycocyanin (APC)-conjugated anti-IgM (clone II/41), PE-conjugated anti-CD40 (clone 1C10), and biotin-conjugated anti-CD40 (clone 3/23) were purchased from BD. APC-conjugated streptavidin was purchased from eBioscience. PE-conjugated anti-hCD25 (clone BC96) and APC-conjugated anti-hCD25 (clone BC96) were purchased from BioLegend. APC-conjugated anti-mCherry (clone 16D7) was purchased from Life Technologies. Staining for intracellular proteins was performed using Cytofix/Cytoperm solution (BD).

### Cell cycle analysis {#s16}

To assess pre--BCR driven proliferation, pre--B cells were resuspended in media without IL-7 and maintained at 2 × 10^6^ cells/ml. 8 h after removal from IL-7, cells were pulsed BrdU for 2 h using the BrdU-FITC kit (BD) per the manufacturer's instructions. DNA content was assessed by 7AAD (BD) or DAPI (Sigma-Aldrich). The SYK kinase inhibitor BAY 61--3606 (EMD Millipore) was used at 10 µM and was added 24 h before IL-7 withdrawal.

### Cell fractionation and Western blot {#s17}

Cell fractionation was performed as previously described ([@bib30]). Western blots were done on whole-cell lysates as previously described ([@bib5]). Anti--NF-κB2 (recognizes p100 and p52; polyclonal), anti-RELB (clone C1E4), anti-BLNK (clone D8R3G), anti-SYK (clone D1I5Q), anti-BTK (clone D3H5), and anti-phospho(S15)-p53 (polyclonal) antibodies were purchased from Cell Signaling Technology. Anti-TRAF2 (polyclonal), anti-TRAF3 (polyclonal), anti-IRF4 (clone E-7), anti-PU.1 (polyclonal), and anti-LaminB (clone G-1) were obtained from Santa Cruz Biotechnology. Anti-phosphorylated BLNK (clone J117-1278) was purchased from BD. Anti-GAPDH (clone GAPDH-71.1) and anti-FLAG (clone M2) were from Sigma-Aldrich. Secondary reagents were horseradish peroxidase (HRP)--conjugated anti--mouse IgG (Cell Signaling Technology) or anti--rabbit IgG (Cell Signaling Technology). Western blots were developed with ECL (Thermo Fisher Scientific) and ECL Prime (GE Healthcare).

### Southern blot {#s18}

Southern blot analyses of coding ends generated during rearrangement at the *Igk* locus were performed on genomic DNA digested with SacI and EcoRI using the JκIII probe and Tcrβ probe, as described previously ([@bib5]).

### RT-PCR {#s19}

RNA was isolated using RNeasy (QIAGEN) and reversed transcribed using either a polyT primer or a random hexamer primer with SuperScriptII (Life Technologies) according to the manufacturers' protocol. RT-PCR was performed using Brilliant II SYBR Green (Agilent) and acquired on an Mx3000P (Stratagene). Each reaction was run in triplicate. Primer sequences are listed in [Table S3](http://www.jem.org/cgi/content/full/jem.20151048/DC1){#supp4}.

### Gene arrays {#s20}

Three independent IL-7 cultures for each genotype (*Rag1^−/−^:μIgH:Bcl2*, *Art^−/−^:μIgH:Bcl2* and *Art^−/−^:Nfkb2^−/−^:μIgH:Bcl2*) were withdrawn from IL-7 for 48 h. RNA was isolated using RNeasy (QIAGEN). Gene expression profiling was performed using Illumina MouseRef-8 expression microarrays by the Washington University Genome Technology Access Center according to the manufacturer's protocols. Data have been deposited in NCBI's Gene Expression Omnibus under accession no. [GSE67854](GSE67854). Differentially expressed genes were identified by error-weighted analysis of variance (ANOVA; Partek Genomics Suite v6.12). Fold changes were calculated based on the mean of three cell lines for each genotype. Only those genes with a fold change of ≥1.5 and a p-value ≤ 0.05 were considered for further analysis. ImmGen (Immunological Genome project) project gene expression data were independently analyzed to identify all genes expression changes that were significantly changed (P \< 0.05) between large and small pre--B cells (datasets: preB_FrC_BM vs. preB_FrD_BM; [@bib22]).

### Chromatin immunoprecipitation (ChIP) {#s21}

ChIP was performed using anti-PU.1 (Santa Cruz Biotechnology), anti-FLAG (Sigma-Aldrich), control rabbit IgG (Santa Cruz Biotechnology), and control mouse IgG antibodies (eBioscience) as previously described ([@bib32]). In brief, DNA from 5 × 10^6^ cells was cross-linked with 1% formaldehyde for 10 min at room temperature Reaction was stopped with 125 µM Glycine. Cells were lysed with NP-40 and nuclei were frozen in liquid nitrogen, and then lysed with SDS. DNA was sonicated with 30-s pulses for 60--90 cycles. DNA fragmentation was in the range of 0.5--1 kb and was monitored by agarose gel electrophoresis. Immunoprecipitation was performed with 1 µg of anti-PU.1 (polyclonal; Santa Cruz Biotechnology) or control rabbit IgG (sc-2027) and protein A--Sepharose beads (Thermo Fisher Scientific). For FLAG ChIP, 2 µg of anti-FLAG (clone M2; Sigma-Aldrich) or control mouse IgG (clone P3.6.2.8.1; eBioscience) was first incubated with rabbit anti-mouse IgG (EMD Millipore) and immunoprecipitation was performed with Protein A Dynabeads (Life Technologies). DNA was purified with QIAquick PCR purification kit (QIAGEN). Quantitative PCR was performed using Brilliant II SYBR Green (Agilent) and acquired on an Mx3000P (Stratagene). Primers are listed in Table S3.

### Statistical analysis {#s22}

For analyses other than gene array, p-values were generated via Student's *t* test (unpaired, two-tailed) using Prism (GraphPad Software).

### Online supplemental material {#s23}

Fig. S1 shows IL-7 culture system for studying RAG DSBs. Table S1 shows genes regulated by RAG DSBs. Table S2 shows genes regulated by NF-κB2. Table S3 shows sequences of primers. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20151048/DC1>.
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